Dolutegravir Switch Maintains Second-Line HIV Suppression
Switching people living with HIV from a ritonavir-boosted protease inhibitor (PI) to a dolutegravir (Tivicay)-based regimen maintained viral suppression just as well, according to a randomized trial out of Kenya. Among a cohort of nearly 800 participants, 5.0% who switched to dolutegravir and 5.1% who continued taking a ritonavir-boosted PI had a plasma HIV type […]